investing.comAUG 282 min read$TEM

Tempus AI CEO Eric Lefkofsky sells $827,856 in stock

Tempus AI CEO Eric Lefkofsky sold 11,848 shares for $827,856, with TEM stock up 33% in six months. Tempus reported Q2 2026 revenue of $382.5M, up 22% YoY but below estimates. Analysts lowered price targets but maintained a Buy rating.

Original reporting

investing.com

Published Aug 28, 2026, 1:12 AM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 28, 2026, 2:11 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefFinancial news

Primary signal

$TEM

Bearish

medium confidence

Mentioned

$TEM

Relevance

5/10

alphai data visualization · based on investing.com

Decision brief

The 30-second read

$TEMBearishMed

Why it matters

Mixed earnings and insider sale create short‑term uncertainty; longer‑term outlook hinges on acquisitions and assay approvals.

Market read

Tempus AI faces near‑term price pressure from insider selling and earnings miss, but strategic moves may support medium‑term upside.

What to watch

Recent xT CDx approval and upcoming Personalis acquisition could offset selling pressure.

Relevance 5/10Novelty 6/10Timing: post‑market today

Background

Tempus AI reported Q2 2026 results with revenue up 22% YoY but missed consensus, prompting analyst target cuts.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TEMBearishMedium confidence

Context

CEO Eric Lefkofsky sold 11,848 shares for $827,856 under a 10b5‑1 plan, indicating insider selling.

Expected impact

Short‑term dip expected; watch for further selling.

Evidence & confidence

Insider sale of $0.8 M suggests reduced confidence; combined with mixed earnings, price may slip.

Market effects

Sector

AI‑driven biotech sector may see modest re‑rating as earnings miss guidance.

Regional

US biotech stocks could face slight pullback.

Global

Limited; primarily affects US‑listed TEM.

Counterpoint

What could challenge this read

Insider sale may be routine under a pre‑established plan; price could stay stable if earnings momentum holds.

Key entities

Executive
Eric Lefkofsky
CEO and Chairman of Tempus AI, executed insider sale.
Analyst
BTIG
Reduced price target to $70.

Read at source ← All news

AUG 28

$TSLALow

Cathie Wood Invested Roughly $1.4 Billion of Ark Invest's Flagship ETF in Just 3 Artificial Intelligence (AI) Stocks

Ark Invest's ARK Innovation ETF, managed by Cathie Wood, allocated $1.4B to three AI-related stocks: Tesla (TSLA) with a $595M position and $2,600 price target by 2029, Tempus AI (TEM) with a $402M position, and SpaceX (SPCX) with a $378M position. The ETF has $6.42B in assets under management.

aol.com3 min

AUG 27

$TEMMedAI 9/10

Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

Tempus AI (TEM) shares rose after Moderna and Merck reported positive Phase 3 trial results for a personalized cancer therapy, validating Personalis' sequencing technology. Tempus agreed to acquire Personalis for $1.5B, with the deal pending. Personalis' technology is distinct from the main target of the acquisition, NeXT Personal, a tumor-informed molecular residual disease test. Tempus reported 9,000 MRD tests in Q2, while Personalis generated $22.357M in revenue and delivered 10,384 clinical

insidermonkey.com3 min

AUG 24

$PSNLMed

Personalis falls amid a downgrade as competive bid appears unlikely

Personalis Inc. (PSNL) fell 6% after Craig-Hallum downgraded it to hold from buy, citing an unlikely higher bid than its announced sale to Tempus AI (TEM). Tempus shares also dropped 7.2%.

seekingalpha.com1 min

AUG 24

$TEMMedAI 8/10

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

Tempus AI, Inc. (NASDAQ: TEM) received FDA clearance for its AI product, Tempus ECG-PH, designed to detect signs of pulmonary hypertension from standard ECGs. This is the third FDA-cleared cardiovascular device in Tempus' portfolio, aiming to help clinicians identify at-risk patients earlier. The product analyzes ECG data but is not intended for standalone diagnosis.

biospace.com2 min

AUG 23

$TEMHighAI 8/10

Why Tempus AI Skyrocketed This Week

Tempus AI (TEM) shares rose 39.5% this week after Merck and Moderna reported positive Phase 3 trial data for their cancer vaccine, which uses technology from Personalis, a company Tempus is acquiring. Tempus's market cap is $13B, and its stock is still down about 10% over the past year. The acquisition is expected to close late 2024 or early 2027.

fool.com2 min

AUG 22

$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.

stockstotrade.com3 min